Knight Non Currrent Assets Other from 2010 to 2024
| GUD Stock | CAD 5.87 0.14 2.44% |
Non Currrent Assets Other | First Reported 2014-03-31 | Previous Quarter 48.2 M | Current Value 47.6 M | Quarterly Volatility 14.4 M |
Check Knight Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Knight Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 75.6 M, Interest Expense of 9.4 M or Selling General Administrative of 87.9 M, as well as many indicators such as Price To Sales Ratio of 1.61, Dividend Yield of 0.5 or PTB Ratio of 0.71. Knight financial statements analysis is a perfect complement when working with Knight Therapeutics Valuation or Volatility modules.
Knight | Non Currrent Assets Other |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectOther Information on Investing in Knight Stock
Knight Therapeutics financial ratios help investors to determine whether Knight Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Knight with respect to the benefits of owning Knight Therapeutics security.